Cancer Systemic Therapy Policy Committee

 

This advisory committee provides the Nova Scotia Department of Health with advice on what cancer drugs should qualify for public funding. The committee is made up of 23 people, including cancer specialists, a cancer survivor, a pharmacist, ethicist other health care providers and members from the Department of Health.

The committee reviews cancer drugs using a values and evidence-based decision making framework. The framework is used to guide discussions around the economics, ethics, and evidence to make recommendations to the Deputy Minister of Health about additions, changes, and deletions to the cancer drug formulary.

• Terms of Reference (PDF)
• Decision Making Framework (PDF)
• Appeal Process (PDF)
• Appeal Form (PDF)

 

Record of Recommendations

• Alemtuzumab (Mab Campath ®)
  • Guideline for use in Chronic Lymphocytic Leukemia (CLL) (PDF)
  • Record of Recommendation in Chronic Lymphocytic Leukemia (CLL) (PDF)
    
    
• Aprepitant (Emend®)
  • Guidelines for Use with Highly Emetogenic Chemotherapy (PDF)
  • Record of Recommendation with Highly Emetogenic Chemotherapy (PDF)
    
    
• Bevacizumab (Avastin ®)
  • Record of Recommendation in Colorectal Cancer (PDF)
  • Guidelines for the Role of Bevacizumab (Avastin®) in Metastatic Colorectal Cancer (MCRC) (PDF)

• Bortezomib (Velcade ®)
  • Guideline for use in Multiple Myeloma (PDF)
  • Record of Recommendation in Multiple Myeloma (PDF)

• Cetuximab (Erbitux ®)
  • Guidelines for the Role of Cetuximab Plus Radiotherapy for Squamous Cell Carcinoma of the Head and Neck (HNSCC) (PDF)
  • Record of Recommendation - Funding Cetuximab (Erbitux ®) in Treatment of Squamous Cell Carcinoma of the Head and Neck(PDF)
    
  • Record of Recommendation for Funding of Cetuximab in Metastatic Colorectal Cancer (PDF)

• Dasatinib (Sprycel ®)
  • Guideline for use in CML & ALL (PDF)
  • Record of Recommendation in MM & ALL (PDF)

• Docetaxel / Cyclophosphamide as Adjuvant Therapy for Breast Cancer
  • Guidelines for the Role of Docetaxel / Cyclophosphamide as Adjuvant Therapy for Breast Cancer (PDF)
  • Record of Recommendation for Docetaxel/Cyclophosphamide (TC) as Adjuvant Therapy in Operable Invasive Breast Cancer (PDF)
    
• lenalidomide (Revlimid ® ) in Multiple Myeloma
  • Record of Recommendation for Funding lenalidomide (Revlimid ® ) in Multiple Myeloma (PDF)

• Oxaliplatin (Eloxatin ®)
• Guideline for the Adjuvant use in Colon Cancer (PDF)
• Record of Recommendation for the Adjuvant use in Colon Cancer (PDF)
  
• Guideline for the use in Metastatic Colorectal Cancer (PDF)
• Record of Recommendation for the use in Metastatic Colorectal Cancer (PDF)

• Pemetrexed (Alimta ®)
  • Guideline for use in Non-Small Cell Lung Cancer (NSCLC) (PDF)
  • Record of Recommendation in Non-Small Cell Lung Cancer (NSCLC) (PDF)
    
• Recombinant Humanized Thyroid Stimulating Hormone (Thyrogen ®)
  • Guideline for use in Thyroid Cancer (PDF)
  • Record of Recommendation in Use in Thyroid Cancer (PDF)
    
• Rituximab (Rituxan ®)
• Guideline for the Maintenance Therapy of NHL (PDF)
• Record of Recommendation as Maintenance Therapy for NHL (PDF)
  
• Guideline for the Treatment of NHL (PDF)
• Record of Recommendation for the Treatment of NHL (PDF)

• Sorafenib (Nexavar ®)
  • Guideline for the use in Renal Cell Carcinoma (RCC) (PDF)
  • Record of Recommendation in RCC (PDF)
    
  • Guideline for the use in Hepatocellular Carcinoma (HCC)
  • Record of Recommendation in Hepatocellular Carcinoma (HCC)

• Sunitinib (Sutent ®)
  • Guideline for the use in RCC (PDF)
  • Record of Recommendation for RCC (PDF)
    
  • Guideline for use in the treatment of GIST (PDF)
  • Record of Recommendation for GIST (PDF)

• Trastuzumab (Herceptin ®)
  • Guideline for use in Adjuvant Breast Cancer (PDF)

• Temsirolimus in Advanced or Metastatic Renal Cell Carcinoma (RCC)
  • Guideline the Role of Temsirolimus in Advanced or Metastatic RCC (PDF)
  • Record of Recommendation for funding Temsirolimus in Advanced or Metastatic RCC (PDF)